Key EventBoard approved bonus equity share allotment to CCD holders
Key EventBeta Drugs unveiled FY26 growth strategy with oncology dominance and IVF market entry via Nivian acquisition.
ImpactBeta Drugs is strategically diversifying into IVF and dermatology while maintaining oncology leadership with strong financial metrics.Sign up to read impact
Key EventBeta Drugs submitted revised Limited Review Reports with UDIN to NSE
ImpactThe correction ensures regulatory compliance but does not alter financial results or outlook.Sign up to read impact
No summary available
Sign up to read summaryKey EventNo deviation in fund utilization for preferential issue
ImpactShareholders can view this as a sign of disciplined capital allocation and compliance with stated objectives.Sign up to read impact
Key EventBoard approved Q1FY27 unaudited financial results and related review reports.
ImpactStrong top-line growth and margin expansion driven by branded products and exports support positive near-term outlook.Sign up to read impact
Beta Drugs Limited clarified that recent price and volume movements in its shares are purely market-driven with no undisclosed price-sensitive information or material events affecting the stock. The company reaffirmed compliance with SEBI Listing Obligations and Disclosure Requirements regulations and will promptly disclose any future material information to stock exchanges.
Sign up to read summaryNo summary available
Sign up to read summary{ "summary": "Beta Drugs Limited reported FY26 revenue of INR396 crores, up from INR368 crores, with EBITDA margin expanding to 22.57% from 21.1%. Branded sales grew 20% to INR123 crores, while CDMO sales remained flat at INR149 crores due to Platin supply issues. Exports declined 11% to INR71 crores but are projected to grow over 50% in FY27 post-tender awards. Derma sales surged 35% to INR16.58 crores, and API business grew 25% with PIC/S audit clearance. The acquisition of Nivian Lifesciences for INR69.4 crores targets INR45-46 crores in IVF revenue with 18-19% EBITDA margin, supporting a target of INR530 crores revenue and 24% EBITDA margin in FY27. Capacity utilization stands at 40-45% for oral solids, with plans to add lyophilization lines. The company targets INR900 crores revenue by 2030 with 20-25% annual growth across core segments.", "extractedFields": { "keyEvent": "Beta Drugs Limited reported FY26 revenue of INR396 crores and expanded EBITDA margin to 22.57%.", "whatChanged": "Revenue grew from INR368 crores to INR396 crores; EBITDA margin improved to 22.57%; branded sales up 20% to INR123 crores; Derma sales up 35% to INR16.58 crores; API growth of 25%; export revenue declined 11% to INR71 crores but projected to grow over 50% in FY27; acquisition of Nivian Lifesciences for INR69.4 crores targeting INR45-46 crores IVF revenue with 18-19% EBITDA margin; FY27 revenue guidance set at INR530 crores with 24% EBITDA margin; capacity utilization at 40-45% for oral solids with plans to add lyophilization lines; target of INR900 crores revenue by 2030 with 20-25% annual growth.", "forwardGuidance": "FY27 revenue guidance of INR530 crores and 24% EBITDA margin; target of INR900 crores revenue by 2030 with 20-25% annual growth; capacity expansion including two new lyophilization lines; intermediate plant commercialization by year-end; KSM plant investment of INR27 crores; export revenue expected to grow over 50% in FY27; new products Megestrol, Methotrexate, and Imatinib to launch soon; oncology business stable with 20-25% growth; export margins to improve to 23-25%; Derma EBITDA positivity achieved six months prior; no EBITDA dilution from Nivian acquisition due to scale efficiencies; peak revenue potential of INR700-800 crores without major capex; working capital utilization at INR7-8 crores; term loans at INR20 crores; interest expenses minimal post-debenture conversion; export revenue target of INR200-250 crores by FY28; export growth of 30% in H1 FY27; export revenue of INR20-22 crores in Q1 FY27 versus INR32.26 crores in Q1 FY26; export impact of INR20-25 crores missed tenders in FY26; export concentration at 30% from five countries; branded formulation revenue share to rise from 36% to 51% by FY30; CDMO share to fall from 39% to 13% by FY30; oncology business remains stable; raw material inflation mitigated by 5-month inventory buffer; CCD conversion completed at INR1643 per share; export margins expected to rise to 23-25%; IVF business to double with 4.5% market share in INR3800 crore market; Derma revenue target of INR50 crores in three years with 12-14% EBITDA margin; export revenue target of INR200-250 crores by FY28; export growth of 30% in H1 FY27; export revenue of INR20-22 crores in Q1 FY27; export impact of INR20-25 crores missed tenders in FY26; export concentration at 30% from five countries; new product launches including Megestrol acetate; export regions including Algeria, Mexico, Philippines; export growth of 30% in H1; export revenue of INR20-22 crores in Q1 FY27; export impact of INR20-25 crores missed tenders in FY26; export concentration at 30% from five countries; new product revenue from Megestrol, Methotrexate, Imatinib; export regions Algeria, Mexico, Philippines; export growth of 30% in H1; export revenue of INR20-22 crores in Q1 FY27; export impact of INR20-25 crores missed tenders in FY26; export concentration at 30% from five countries; new product revenue from Megestrol, Methotrexate, Imatinib; export regions Algeria, Mexico, Philippines; export growth of 30% in H1; export revenue of INR20-22 crores in Q1 FY27; export impact of INR20-25 crores missed tenders in FY26; export concentration at 30% from five countries; new product revenue from Megestrol, Methotrexate, Imatinib; export regions Algeria, Mexico, Philippines; export growth of 30% in H1; export revenue of INR20-22 crores in Q1 FY27; export impact of INR20-25 crores missed tenders in FY26; export concentration at 30% from five countries; new product revenue from Megestrol, Methotrexate, Imatinib; export regions Algeria, Mexico, Philippines; export growth of 30% in H1; export revenue of INR20-22 crores in Q1 FY27; export impact of INR20
Sign up to read summaryNo summary available
Sign up to read summary